Latest Monoclonal antibodies Stories
Developing Next Generation Cancer Immunotherapy with "Off-the-Shelf" Chimeric Antigen Receptor-Tumor Attacking Natural Killer (CAR-TNK(TM)) Cell Lines SAN DIEGO and CARDIFF-BY-THE-SEA,
MONROVIA, Calif., Dec. 18, 2014 /PRNewswire/ -- Xencor, Inc.
CAMBRIDGE, England, December 16, 2014 /PRNewswire/ -- Crescendo Biologics Limited (Crescendo) today announces a further equity investment from Astellas Venture Management
SAN DIEGO, Dec. 15, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc.
ReportsandReports.com adds latest reports on Adalimumab Industry for Global and China Markets to its store. DALLAS, Dec.
ROCHESTER, N.Y., Dec.
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.
Symphogen has licensed the rights to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of recombinant monoclonal antibody (MAb) mixtures for the treatment
More Images (1 images) »